期刊
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
卷 38, 期 1, 页码 33-42出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jop.2021.0074
关键词
quininib drug series; ocular angiogenesis; cysteinyl leukotriene receptors; zebrafish; phenotype-based drug discovery
The quininib series is a collection of small-molecule drugs with various activities, including antiangiogenic, antivascular permeability, anti-inflammatory, and antiproliferative effects. It has the potential to be used as a therapeutic target for retinal vasculopathies and ocular cancers.
The quininib series is a novel collection of small-molecule drugs with antiangiogenic, antivascular permeability, anti-inflammatory, and antiproliferative activity. Quininib was initially identified as a drug hit during a random chemical library screen for determinants of developmental ocular angiogenesis in zebrafish. To enhance drug efficacy, novel quininib analogs were designed by applying medicinal chemistry approaches. The resulting quininib drug series has efficacy in in vitro and ex vivo models of angiogenesis utilizing human cell lines and tissues. In vivo, quininib drugs reduce pathological angiogenesis and retinal vascular permeability in rodent models. Quininib acts as a cysteinyl leukotriene (CysLT) receptor antagonist, revealing new roles of these G-protein-coupled receptors in developmental angiogenesis of the eye and unexpectedly in uveal melanoma (UM). The quininib series highlighted the potential of CysLT receptors as therapeutic targets for retinal vasculopathies (e.g., neovascular age-related macular degeneration, diabetic retinopathy, and diabetic macular edema) and ocular cancers (e.g., UM).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据